Sequent Scientific Ltd.

NSE: SEQUENT | BSE: 512529 | ISIN: INE807F01027 |Industry: Pharmaceuticals
|Expensive Star
148.10 -0.20 (-0.13%)
NSE Oct 28, 2020 15:58 PM
Volume: 668.7K

Sequent Scientific Ltd.    
13 May 2020
Nirmal Bang Institutional
Sequent Scientific or SSL's 4QFY20 revenue at Rs3,006mn was lower than our estimate by 19.9%. Revenue grew by 6.6% YoY and was led by growth in both API and formulation sales across geographies except Emerging Markets (EM). Gross margin improved 140bps QoQ, primarily led by an increase in API sales and strong performance in Turkey, which is a higher margin business. With API business expected to get stronger from here on and no headwinds in Turkey, we should see margin further build up from current levels. The larger margin driver in the near to medium term would be the first generic launch of injectable in Europe. For FY21, the company has refrained from giving a...
Sequent Scientific Ltd. is trading above it's 200 day SMA of 103.0
More from Sequent Scientific Ltd.